Main Menu

Target Validation and DNA Damage Response Team

Prof. Tutt’s team interests involve the discovery of novel therapies and biomarkers in BRCA1/BRCA2-associated cancers and ER/HER2-negative/basal-like breast cancers – including the identification of new drug targets and therapy combination strategies.

Team members

Dr Nick Balan

Higher Scientific Officer

Dr Kathryn Davidson

Higher Scientific Officer

Dr Callum Walker

Postdoctoral Fellow

Dr Daniel Weekes

Senior Scientific Officer